Saturday 17 October 2026
Export NRXS’s income statement to Excel — free account
Neuraxis, Inc.
NRXS Healthcare Biotechnology
Neuraxis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.6 million, up 32.9% from fiscal 2024. In the quarter to June 2026, revenue grew 115.7%, EPS grew 13.6% and free cash flow grew 29.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.70
0.04
−0.52%
Follow NRXS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 1.80 | 2.00 | 1.33 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | 6.93 | 3.89 | 6.20 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 18 | 19 | 21 | 24 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.15 | 0.13 | 0.13 | 0.15 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 2 | 3 | 3 | 2 | 3 | 4 | ||||
| Gross margin, % | — | — | — | — | 75.08 | 82.81 | 88.94 | 87.67 | 86.52 | 84.23 | |||||
| EBT | — | — | — | — | (4) | (3) | (5) | (15) | (8) | (8) | |||||
| EBT margin, % | — | — | — | — | (193.04) | (111.27) | (178.05) | (594.58) | (306.84) | (218.55) | |||||
| Net income | — | — | — | — | (4) | (3) | (5) | (15) | (8) | (8) | |||||
| Depreciation | — | — | — | — | 0 | 0 | 0 | 5 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.31 | 0.44 | 1.34 | 0.76 | 0.39 | 0.39 | ||||
| Earnings | — | — | — | — | (0.70) | (0.62) | (2.77) | (4.50) | (1.22) | (0.95) | |||||
| Cash flow | — | — | — | — | (0.67) | (0.36) | (1.15) | (2.06) | (0.88) | (0.71) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | (0.03) | (0.02) | 0.00 | (0.01) | |||||
| Free cash flow | — | — | — | — | (0.67) | (0.36) | (1.18) | (2.08) | (0.89) | (0.72) | |||||
| Book value | — | — | — | — | 0.27 | (0.13) | (2.78) | (0.43) | 0.30 | 0.37 | |||||
| Shares, m | — | — | — | — | 6 | 6 | 2 | 3 | 7 | 9 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | 4.48 | 4.48 | 4.48 | 3.36 | 6.05 | 11.55 | |||||
| P/B | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 7.88 | 12.14 | |||||
| EV/Sales | — | — | — | — | 4.48 | 4.48 | 4.48 | 3.34 | 4.69 | 10.17 | |||||
| EV/FCF | — | — | — | — | (5.03) | (5.03) | (5.03) | (1.21) | (2.03) | (5.50) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (4) | (2) | (2) | (7) | (6) | (6) | ||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | (4) | (2) | (2) | (7) | (6) | (7) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 1 | (1) | (7) | (2) | 2 | 3 | ||||
| Total debt | — | — | — | — | 0 | 0 | 1 | — | — | — | |||||
| Net debt | — | — | — | — | (2) | 0 | 0 | 0 | (4) | (5) | |||||
| Shareholders’ equity | — | — | — | — | 2 | (1) | (6) | (1) | 2 | 3 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (212.78) | (426.59) | (1,469.95) | (320.97) | (154.37) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | 0.00 | (924.80) | 149.37 | 419.26 | (2,560.29) | (315.63) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Neuraxis, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PYPD PolyPid Ltd. | $99.5M | — (loss-making) | — | — | n/m | −64.96% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MIST Milestone Pharmaceuticals Inc. | $98.9M | — (loss-making) | — (loss-making) | −62.73% (below 0%: shrinking) | n/m | −80.81% (below 0%: shrinking) | 94.28% | (4,584.97%) | Compare |
| CBUS Cibus, Inc. | $98.6M | — (loss-making) | — (loss-making) | +6.54% (above 0%: growing) | n/m | +31.62% (above 0%: growing) | 100.00% | (1,300.30%) | Compare |
| PMVP PMV Pharmaceuticals, Inc. | $97.4M | — (loss-making) | — | — | n/m | +20.27% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NRXS Neuraxis, Inc. | $97.2M | — (loss-making) | — (loss-making) | +115.71% (above 0%: growing) | n/m | +29.76% (above 0%: growing) | 85.87% | (110.16%) | |
| IMUX Immunic, Inc. | $96.9M | — (loss-making) | — | — | n/m | −26.79% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ATRA Atara Biotherapeutics, Inc. | $96.9M | — (loss-making) | — (loss-making) | −96.42% (below 0%: shrinking) | n/m | +52.10% (above 0%: growing) | 69.68% | (749.21%) | Compare |
| ANIX ANIXA BIOSCIENCES INC | $96.7M | — (loss-making) | — (loss-making) | 0.00% | n/m | −17.14% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ICCC ImmuCell Corporation | $95.9M | 126× | — (loss-making) | +11.50% (above 0%: growing) | +233.33% (above 0%: growing) | +54.86% (above 0%: growing) | 33.92% | 26.93% | Compare |
| Median of peers | $97.1M | — | — | 0.00% | — | +1.56% | 16.96% | 0.00% |
Neuraxis, Inc. (NRXS) key facts
- Strength: Neuraxis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.6 million, up 32.9% from fiscal 2024.
- Neuraxis, Inc. (NRXS) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
- As of October 16, 2026, NRXS traded at $7.70, a market capitalization of $97.2 million.
- Return on equity was −315.6% and debt-to-equity 0.00.
- Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −8.81 (distress zone) for fiscal 2025.